- Home
- WCN vs TAK Comparison
WCN vs TAK Comparison
Compare WCN & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WCN
- TAK
- Stock Information
- Founded
- WCN 1997
- TAK 1781
- Country
- WCN Canada
- TAK Japan
- Employees
- WCN N/A
- TAK N/A
- Industry
- WCN Power Generation
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- WCN Utilities
- TAK Health Care
- Exchange
- WCN Nasdaq
- TAK Nasdaq
- Market Cap
- WCN 48.9B
- TAK 45.8B
- IPO Year
- WCN 1998
- TAK N/A
- Fundamental
- Price
- WCN $185.70
- TAK $14.76
- Analyst Decision
- WCN Strong Buy
- TAK
- Analyst Count
- WCN 16
- TAK 0
- Target Price
- WCN $210.06
- TAK N/A
- AVG Volume (30 Days)
- WCN 853.4K
- TAK 1.9M
- Earning Date
- WCN 07-23-2025
- TAK 07-30-2025
- Dividend Yield
- WCN 0.68%
- TAK 4.01%
- EPS Growth
- WCN N/A
- TAK N/A
- EPS
- WCN 2.43
- TAK 0.45
- Revenue
- WCN $9,075,114,000.00
- TAK $30,595,075,281.00
- Revenue This Year
- WCN $7.94
- TAK $1.01
- Revenue Next Year
- WCN $7.09
- TAK $1.04
- P/E Ratio
- WCN $76.58
- TAK $63.71
- Revenue Growth
- WCN 10.75
- TAK 7.45
- 52 Week Low
- WCN $169.36
- TAK $12.58
- 52 Week High
- WCN $201.66
- TAK $15.43
- Technical
- Relative Strength Index (RSI)
- WCN 35.86
- TAK 46.62
- Support Level
- WCN $185.52
- TAK $14.86
- Resistance Level
- WCN $192.72
- TAK $15.42
- Average True Range (ATR)
- WCN 2.63
- TAK 0.14
- MACD
- WCN -0.63
- TAK -0.03
- Stochastic Oscillator
- WCN 5.41
- TAK 9.47
About WCN Waste Connections Inc.
Waste Connections is the third-largest integrated provider of traditional solid waste and recycling services in the North America, operating 113 active landfills (20 are exploration and production waste landfills and 16 are nonmunicipal waste landfills), 163 transfer stations, and 89 recycling operations. The firm serves residential, commercial, industrial, and energy end markets. Waste Connections entered the Canadian market with its 2016 merger with Progressive Waste. In 2024, 14% of consolidated revenue was generated from the firm's Canadian segment.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.